# reload+after+2024-01-19 23:36:04.711389
address1§24 Cheshire Avenue
address2§Cheshire Business Park Lostock Gralam
city§Northwich
zip§CW9 7UA
country§United Kingdom
phone§44 1606 814730
fax§44 1606 814731
website§https://www.dechra.com
industry§Drug Manufacturers - General
industryKey§drug-manufacturers-general
industryDisp§Drug Manufacturers - General
sector§Healthcare
sectorKey§healthcare
sectorDisp§Healthcare
longBusinessSummary§Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
fullTimeEmployees§2457
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Ian D. Page', 'age': 62, 'title': 'CEO, MD & Executive Director', 'yearBorn': 1961, 'fiscalYear': 2023, 'totalPay': 848000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul Nicholas Sandland MAAT, FCCA', 'age': 44, 'title': 'CFO & Executive Director', 'yearBorn': 1979, 'fiscalYear': 2023, 'totalPay': 559000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Patrick  Meeus', 'title': 'Chief Scientific Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jamie  Adams', 'title': 'Chief Information Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Katy  Clough', 'title': 'Chief People Officer', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mike  Eldred', 'age': 53, 'title': 'President of North America', 'yearBorn': 1970, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Melanie Jane Hall', 'title': 'Company Secretary', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§9
compensationRisk§8
shareHolderRightsRisk§10
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§2
dividendRate§0.45
dividendYield§0.012
exDividendDate§1678320000
payoutRatio§1.2511001
fiveYearAvgDividendYield§1.1
beta§0.781
priceToSalesTrailing12Months§5.7708383
currency§GBp
forwardEps§146.14
pegRatio§4.87
lastDividendValue§12.5
lastDividendDate§1678320000
exchange§LSE
quoteType§EQUITY
shortName§DECHRA PHARMACEUTICALS PLC ORD 
longName§Dechra Pharmaceuticals PLC
firstTradeDateEpochUtc§969519600
timeZoneFullName§Europe/London
timeZoneShortName§GMT
uuid§83b47dbc-fbd2-3d06-819e-d3a387c882f3
messageBoardId§finmb_137717
targetHighPrice§5000.0
targetLowPrice§3875.0
targetMeanPrice§4117.14
targetMedianPrice§4000.0
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§7
quickRatio§1.488
grossMargins§0.56415004
ebitdaMargins§0.08168
trailingPegRatio§None
